NEVVI Medicare utilization intelligence

← back

HACKETT, LEONARDM.D. NPI 1669466868 Clinician

Hematology · FRESNO, CA

Specialty Hematology — from billed Medicare claims
In practice about 49 years since medical school (class of 1977, self-reported to CMS)
Location FRESNO, CA · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 92 codes billed · 288,101 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2025-10

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9299 Injection, nivolumab, 1 mg
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
J1439 Injection, ferric carboxymaltose, 1 mg
J0897 Injection, denosumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J1437 Injection, ferric derisomaltose, 10 mg
J2796 Injection, romiplostim, 10 micrograms
J1627 Injection, granisetron, extended-release, 0.1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1071 Injection, testosterone cypionate, 1 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J9267 Injection, paclitaxel, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
80053 Blood test, comprehensive group of blood chemicals
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
96372 Injection of drug or substance under skin or into muscle
J9041 Injection, bortezomib, 0.1 mg
82728 Ferritin (blood protein) level
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
J2469 Injection, palonosetron hcl, 25 mcg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
83540 Iron level
83550 Iron binding capacity
J0640 Injection, leucovorin calcium, per 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J9190 Injection, fluorouracil, 500 mg
96413 Administration of chemotherapy into vein, 1 hour or less
82664 Electrophoresis, laboratory testing technique
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J9045 Injection, carboplatin, 50 mg
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
82784 Gammaglobulin (immune system protein) measurement
J2919 Injection, methylprednisolone sodium succinate, 5 mg
83615 Lactate dehydrogenase (enzyme) level
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3490 Unclassified drugs
84153 Psa (prostate specific antigen) measurement, total
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
J1200 Injection, diphenhydramine hcl, up to 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
85610 Blood test, clotting time
96375 Injection of additional new drug or substance into vein
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99195 Drawing of blood for a medical problem
84439 Thyroxine (thyroid chemical), free
99490 Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
82607 Cyanocobalamin (vitamin b-12) level
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
82378 Carcinoembryonic antigen (cea) protein level
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
83010 Haptoglobin (serum protein) level
82746 Folic acid level, serum
96416 Administration of prolonged chemotherapy into vein
99439 Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month
83735 Magnesium level
84550 Uric acid level, blood
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
J2997 Injection, alteplase recombinant, 1 mg
74177 Ct scan of abdomen and pelvis with contrast
81002 Urinalysis, manual test
96411 Administration of additional new drug or substance into vein using push technique
G0008 Administration of influenza virus vaccine
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
71260 Ct scan of chest with contrast
90662 Influenza vaccine split virus, preservative free
78816 Nuclear medicine study whole body with ct scan
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
84481 Thyroid hormone, t3 measurement, free
74176 Ct scan of abdomen and pelvis without contrast
36593 Declotting of central venous tube
88184 Flow cytometry technique for dna or cell analysis, first marker
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.